These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 21738339)
41. Accuracy of multi-detector computed tomography, fluorodeoxyglucose positron emission tomography-CT, and CA 19-9 levels in detecting recurrent pancreatic adenocarcinoma. Hamidian Jahromi A; Sangster G; Zibari G; Martin B; Chu Q; Takalkar A; Shi R; Shokouh-Amiri H JOP; 2013 Jul; 14(4):466-8. PubMed ID: 23846950 [TBL] [Abstract][Full Text] [Related]
42. Clinical usefulness of F-18 FDG PET in lymphoepithelioma-like gastric carcinoma. Park S; Lee D; Lee KM; Han SU; Lee JH; Lee SJ; An YS; Yoon JK Eur J Radiol; 2017 Sep; 94():160-166. PubMed ID: 28712702 [TBL] [Abstract][Full Text] [Related]
43. [Value of (18)F-FDG PET/CT and CECT in detecting postoperative recurrence and extrahepatic metastasis of hepatocellular carcinoma in patients with elevated serum alpha-fetoprotein]. Chen Z; Liang H; Zhang X; Wang X; Chen W; Shi X; Yi C; Rao L Nan Fang Yi Ke Da Xue Xue Bao; 2012 Nov; 32(11):1615-9. PubMed ID: 23174588 [TBL] [Abstract][Full Text] [Related]
44. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer. Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451 [TBL] [Abstract][Full Text] [Related]
45. Impact of positron emission tomography/computed tomography in the management of patients with epithelial ovarian carcinoma after treatment. Nasu K; Abe W; Takai N; Tomonari K; Narahara H Arch Gynecol Obstet; 2011 May; 283(5):1121-6. PubMed ID: 20574659 [TBL] [Abstract][Full Text] [Related]
46. Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer. Schmidt GP; Baur-Melnyk A; Haug A; Utzschneider S; Becker CR; Tiling R; Reiser MF; Hermann KA Eur Radiol; 2009 Jun; 19(6):1366-78. PubMed ID: 19190917 [TBL] [Abstract][Full Text] [Related]
48. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088 [TBL] [Abstract][Full Text] [Related]
49. The clinical value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in postoperative patients with gastrointestinal mucinous adenocarcinoma. Yang ZY; Hu SL; Shi W; Zhu BL; Xu JY; Zhang YJ Nucl Med Commun; 2011 Nov; 32(11):1018-25. PubMed ID: 21956489 [TBL] [Abstract][Full Text] [Related]
50. PET/CT pattern analysis for surgical staple line recurrence in patients with colorectal cancer. Shyn PB; Madan R; Wu C; Erturk SM; Silverman SG AJR Am J Roentgenol; 2010 Feb; 194(2):414-21. PubMed ID: 20093604 [TBL] [Abstract][Full Text] [Related]
52. Detection of neck recurrence in patients with differentiated thyroid cancer: comparison of ultrasound, contrast-enhanced CT and (18)F-FDG PET/CT using surgical pathology as a reference standard: (ultrasound vs. CT vs. (18)F-FDG PET/CT in recurrent thyroid cancer). Seo YL; Yoon DY; Baek S; Ku YJ; Rho YS; Chung EJ; Koh SH Eur Radiol; 2012 Oct; 22(10):2246-54. PubMed ID: 22562091 [TBL] [Abstract][Full Text] [Related]
53. The impact of 18F-FDG PET/CT in patients with liver metastases. Chua SC; Groves AM; Kayani I; Menezes L; Gacinovic S; Du Y; Bomanji JB; Ell PJ Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1906-14. PubMed ID: 17713766 [TBL] [Abstract][Full Text] [Related]
54. 18 F-fluorodeoxyglucose positron emission tomography to evaluate recurrent gastric cancer: a systematic review and meta-analysis. Wu LM; Hu JN; Hua J; Gu HY; Zhu J; Xu JR J Gastroenterol Hepatol; 2012 Mar; 27(3):472-80. PubMed ID: 21916986 [TBL] [Abstract][Full Text] [Related]
55. Role of ¹⁸F-FDG PET/CT in the prediction of gastric cancer recurrence after curative surgical resection. Lee JW; Lee SM; Lee MS; Shin HC Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1425-34. PubMed ID: 22673973 [TBL] [Abstract][Full Text] [Related]
56. To Enhance or Not to Enhance? The Role of Contrast Medium Massollo M; Fiz F; Bottoni G; Ugolini M; Paparo F; Puppo C; Provinciali N; Iacozzi M; Altrinetti V; Cistaro A; Cabria M; DeCensi A; Treglia G; Piccardo A Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34206116 [No Abstract] [Full Text] [Related]
57. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma. Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135 [TBL] [Abstract][Full Text] [Related]
58. Role of FDG-PET/CT in follow-up of patients treated with resective gastric surgery for tumour. Graziosi L; Bugiantella W; Cavazzoni E; Cantarella F; Porcari M; Baffa N; Donini A Ann Ital Chir; 2011; 82(2):125-9. PubMed ID: 21682102 [TBL] [Abstract][Full Text] [Related]
59. The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis. Daamen LA; Groot VP; Goense L; Wessels FJ; Borel Rinkes IH; Intven MPW; van Santvoort HC; Molenaar IQ Eur J Radiol; 2018 Sep; 106():128-136. PubMed ID: 30150034 [TBL] [Abstract][Full Text] [Related]
60. Diagnostic Performance of ¹⁸F-FDG PET and PET/CT for the Detection of Recurrent Esophageal Cancer After Treatment with Curative Intent: A Systematic Review and Meta-Analysis. Goense L; van Rossum PS; Reitsma JB; Lam MG; Meijer GJ; van Vulpen M; Ruurda JP; van Hillegersberg R J Nucl Med; 2015 Jul; 56(7):995-1002. PubMed ID: 25952733 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]